Jpmorgan Chase & CO Syndax Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,105,807 shares of SNDX stock, worth $16.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,105,807
Previous 897,317 23.23%
Holding current value
$16.8 Million
Previous $11.9 Million 14.57%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$12.29 - $16.38 $2.56 Million - $3.42 Million
208,490 Added 23.23%
1,105,807 $13.6 Million
Q4 2024

Feb 12, 2025
BUY
$12.52 - $21.81 $3.38 Million - $5.88 Million
269,638 Added 42.96%
897,317 $11.9 Million
Q3 2024

Dec 26, 2024
SELL
$17.93 - $24.81 $39,463 - $54,606
-2,201 Reduced 0.35%
627,679 $12.1 Million
Q3 2024

Nov 08, 2024
SELL
$17.93 - $24.81 $39,463 - $54,606
-2,201 Reduced 0.35%
627,679 $12.1 Million
Q2 2024

Dec 26, 2024
BUY
$18.82 - $23.79 $41,422 - $52,361
2,201 Added 0.35%
629,880 $12.9 Million
Q2 2024

Aug 12, 2024
SELL
$18.82 - $23.79 $989,630 - $1.25 Million
-52,584 Reduced 7.71%
629,880 $12.9 Million
Q1 2024

Dec 26, 2024
BUY
$19.71 - $24.57 $1.08 Million - $1.35 Million
54,785 Added 8.73%
682,464 $16.2 Million
Q1 2024

May 10, 2024
SELL
$19.71 - $24.57 $1.94 Million - $2.42 Million
-98,466 Reduced 12.61%
682,464 $16.2 Million
Q4 2023

Dec 26, 2024
BUY
$11.39 - $21.67 $1.75 Million - $3.32 Million
153,251 Added 24.42%
780,930 $16.9 Million
Q4 2023

Feb 12, 2024
BUY
$11.39 - $21.67 $590,366 - $1.12 Million
51,832 Added 7.11%
780,930 $16.9 Million
Q3 2023

Nov 14, 2023
SELL
$14.52 - $21.77 $604,365 - $906,132
-41,623 Reduced 5.4%
729,098 $10.6 Million
Q2 2023

Aug 11, 2023
BUY
$19.35 - $22.31 $4.29 Million - $4.94 Million
221,636 Added 40.36%
770,721 $16.1 Million
Q1 2023

May 18, 2023
BUY
$20.66 - $28.98 $1.61 Million - $2.25 Million
77,776 Added 16.5%
549,085 $11.6 Million
Q1 2023

May 11, 2023
SELL
$20.66 - $28.98 $1.38 Million - $1.94 Million
-66,817 Reduced 12.42%
471,309 $9.95 Million
Q4 2022

Feb 13, 2023
SELL
$20.64 - $26.24 $1.61 Million - $2.05 Million
-78,125 Reduced 12.68%
538,126 $13.7 Million
Q3 2022

Nov 14, 2022
BUY
$18.51 - $24.79 $406,275 - $544,115
21,949 Added 3.69%
616,251 $14.8 Million
Q2 2022

Aug 11, 2022
BUY
$13.64 - $19.48 $4.84 Million - $6.91 Million
354,473 Added 147.8%
594,302 $11.4 Million
Q1 2022

May 11, 2022
BUY
$14.84 - $22.15 $1.03 Million - $1.54 Million
69,356 Added 40.68%
239,829 $4.17 Million
Q4 2021

Feb 10, 2022
BUY
$15.23 - $22.47 $1.45 Million - $2.15 Million
95,491 Added 127.35%
170,473 $3.73 Million
Q3 2021

Nov 12, 2021
BUY
$13.87 - $19.8 $1.04 Million - $1.48 Million
74,982 New
74,982 $1.43 Million

Others Institutions Holding SNDX

# of Institutions
247
Shares Held
100M
Call Options Held
1.28M
Put Options Held
1.29M
View Full List

About Syndax Pharmaceuticals Inc

SNDX Quotes by TradingView
  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $860M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email